Ngā hua rapu - C.L. Beach

  • E whakaatu ana i te 1 - 20 hua o te 20
Whakamahine hua
  1. 1
    Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B

    Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B mā Lewis R. Silverman, David R. McKenzie, Bercedis L. Peterson, James F. Holland, Jay T. Backstrom, C. L. Beach, Richard A. Larson

    I whakaputaina 2006
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial

    A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care... mā Steven D. Gore, Pierre Fenaux, Valeria Santini, John M. Bennett, L.R. Silverman, John F. Seymour, Eva Hellström‐Lindberg, Arlene S. Swern, C.L. Beach, Alan F. List

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes

    Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes mā John F. Seymour, Pierre Fenaux, Lewis R. Silverman, Ghulam J. Mufti, Eva Hellström‐Lindberg, Valeria Santini, Alan F. List, Steven D. Gore, Jay T. Backstrom, David R. McKenzie, C.L. Beach

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

    Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure mā Thomas Prébet, Steven D. Gore, Benjamin Esterni, Claude Gardin, Raphaël Itzykson, Sylvain Thépot, François Dreyfus, Odile Beyne Rauzy, Christian Récher, Lionel Adès, Bruno Quesnel, C.L. Beach, Pierre Fenaux, Norbert Vey

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

    Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML... mā Amer M. Zeidan, James D. Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac W. Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, Tim O'Connor, Shelonitda Rose, C.L. Beach, Lewis R. Silverman

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Prognostic impact of <i>NPM1</i> and <i>FLT3</i> mutations in patients with AML in first remission treated with oral azacitidine

    Prognostic impact of <i>NPM1</i> and <i>FLT3</i> mutations in patients with AML in first remission treated with oral azacitidine mā Hartmut Döhner, Andrew H. Wei, Gail J. Roboz, Pau Montesinos, Felicitas Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L. See, Manuel Ugidos, Alberto Risueño, Esther T. Chan, Anjan Thakurta, C.L. Beach, Daniel L. Menezes

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

    Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia mā Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg, Valeria Santini, Norbert Gattermann, Ulrich Germing, Guillermo Sanz, Alan F. List, Steven D. Gore, John F. Seymour, Hervé Dombret, Jay T. Backstrom, Linda Zimmerman, David R. McKenzie, C.L. Beach, Lewis R. Silverman

    I whakaputaina 2009
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care

    Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care mā Hartmut Döhner, Anna Dolnik, Lin Tang, John F. Seymour, Mark D. Minden, Richard M. Stone, Teresa Bernal, Haifa Kathrin Al‐Ali, Valeria Santini, Paresh Vyas, C.L. Beach, Kyle J. MacBeth, Barry Skikne, S. Songer, Nora Tu, Lars Bullinger, Hervé Dombret

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

    A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML mā Amer M. Zeidan, Isaac W. Boss, C.L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa Hasle, Andrzej Hellmann, David Taussig, Mar Tormo, Maria Teresa Voso, James D. Cavenagh, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Lewis R. Silverman

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status

    Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status mā Gail J. Roboz, Farhad Ravandi, Andrew H. Wei, Hervé Dombret, Felicitas Thol, Maria Teresa Voso, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, Judy Zhong, C.L. Beach, Alberto Risueño, Daniel L. Menezes, Gert J. Ossenkoppele, Hartmut Döhner

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

    A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes mā Amer M. Zeidan, Isaac W. Boss, C.L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa Hasle, K. OGASAWARA, James D. Cavenagh, Lewis R. Silverman, Maria Teresa Voso, Andrzej Hellmann, Mar Tormo, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Guillermo Garcia‐Manero

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

    Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study mā Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg, Valeria Santini, Carlo Finelli, Aristoteles Giagounidis, Robert Schoch, Norbert Gattermann, Guillermo Sanz, Alan F. List, Steven D. Gore, John F. Seymour, John M. Bennett, John C. Byrd, Jay T. Backstrom, Linda Zimmerman, David R. McKenzie, C.L. Beach, Lewis R. Silverman

    I whakaputaina 2009
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

    Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens mā John F. Seymour, Hartmut Döhner, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James D. Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal, Haifa Kathrin Al‐Ali, José Falantes, Richard M. Stone, Mark D. Minden, Jerry Weaver, S. Songer, C.L. Beach, Hervé Dombret

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts

    International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts mā Hervé Dombret, John F. Seymour, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James D. Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal, Haifa Kathrin Al‐Ali, Giovanni Martinelli, José Falantes, Richard Noppeney, Richard M. Stone, Mark D. Minden, Heidi McIntyre, S. Songer, Lela M. Lucy, C. L. Beach, Hartmut Döhner

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

    Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine mā Raphaël Itzykson, Sylvain Thépot, Bruno Quesnel, François Dreyfus, Odile Beyne‐Rauzy, Pascal Turlure, Norbert Vey, Christian Récher, Caroline Dartigeas, Laurence Legros, Jacques Delaunay, Célia Salanoubat, Sorin Visanica, Aspasia Stamatoullas, Françoise Isnard, Anne Marfaing‐Koka, Stéphane de Botton, Youcef Chelghoum, Anne‐Laure Taksin, Isabelle Plantier, Shanti Amé, Simone Boehrer, Claude Gardin, C.L. Beach, Lionel Adès, Pierre Fenaux

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis

    Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative D... mā John Koreth, Joseph Pidala, Waleska S. Pérez, H. Joachim Deeg, Guillermo Garcia‐Manero, Luca Malcovati, Mario Cazzola, Sophie Park, Raphaël Itzykson, Lionel Adès, Pierre Fenaux, Martin Jädersten, Eva Hellström‐Lindberg, Robert Peter Gale, C. L. Beach, Stephanie J. Lee, Mary M. Horowitz, Peter L. Greenberg, Martin S. Tallman, John F. DiPersio, Donald Bunjes, Daniel J. Weisdorf, Corey Cutler

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group

    Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Aust... mā Lisa Pleyer, Hartmut Döhner, Hervé Dombret, John F. Seymour, Andre C. Schuh, C.L. Beach, Arlene S. Swern, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Heinz Sill, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl Spandl, Armin Zebisch, Angelika Pichler, Michael Pfeilstöcker, Eva Maria Autzinger, Alois Lang, Klaus Geißler, Daniela Voskova, Wolfgang R. Sperr, Sabine Hojas, Inga Mandac Rogulj, Johannes Andel, Richard Greil

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

    Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes mā Guillermo Garcia‐Manero, Valeria Santini, António Almeida, Uwe Platzbecker, Anna Jonášová, Lewis R. Silverman, José Falantes, Gianluigi Reda, Francesco Buccisano, Pierre Fenaux, Rena Buckstein, María Díez‐Campelo, Stephen Larsen, David Valcárcel, Paresh Vyas, Valentina Giai, Esther Natalie Olíva, Jake Shortt, Dietger Niederwieser, Moshe Mittelman, Luana Fianchi, Ignazia La Torre, Judy Zhong, Eric Laille, Daniel L. Menezes, Barry Skikne, C.L. Beach, Aristoteles Giagounidis

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

    The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patien... mā Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Pau Montesinos, Boris V. Afanasyev, Hervé Dombret, Farhad Ravandi, Hamid Sayar, Jun Ho Jang, Kimmo Porkka, Dominik Selleslag, Irwindeep Sandhu, Mehmet Turgut, Valentina Giai, Yishai Ofran, Merih Kızıl Çakar, Aïda Botelho de Sousa, Justyna Rybka, Chiara Frairia, Lorenza Borin, Germana Beltrami, Jaroslav Čermák, Gert J. Ossenkoppele, Ignazia La Torre, Barry Skikne, Keshava Kumar, Qian Dong, C.L. Beach, Gail J. Roboz

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

    Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission mā Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Pau Montesinos, Boris V. Afanasyev, Hervé Dombret, Farhad Ravandi, Hamid Sayar, Jun‐Ho Jang, Kimmo Porkka, Dominik Selleslag, Irwindeep Sandhu, Mehmet Turgut, Valentina Giai, Yishai Ofran, Merih Kızıl Çakar, Aïda Botelho de Sousa, Justyna Rybka, Chiara Frairia, Lorenza Borin, Germana Beltrami, Jaroslav Čermák, Gert J. Ossenkoppele, Ignazia La Torre, Barry Skikne, Keshava Kumar, Qian Dong, C.L. Beach, Gail J. Roboz

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: